Myelodysplastic Syndromes Therapeutics
1. Grafapex patent expiration
Treatment: Administering treosulfan as a preparative regimen for allogeneic stem cell transplantation
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7199162 | MEDEXUS | Use of treosulfan for patient conditioning before bone marrow or blood stem cell transplantation |
Mar, 2026
(2 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jan 21, 2030 |
| Orphan Drug Exclusivity(ODE-513) | Jan 21, 2032 |
| Orphan Drug Exclusivity(ODE-514) | Jan 21, 2032 |
Drugs and Companies using TREOSULFAN ingredient
NCE-1 date: 21 January, 2029
Market Authorisation Date: 21 January, 2025
Dosage: POWDER
More Information on Dosage
GRAFAPEX family patents
2. Revlimid patent expiration
Treatment: Use of revlimid (lenalidomide) while preventing the exposure of a fetus or other contraindicated individual to revlimid (lenalidomide); Use of revlimid (lenalidomide) for the treatment of mantle cell ...
REVLIMID's oppositions filed in EPO
REVLIMID IPR and PTAB Proceedings
Can you believe REVLIMID received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8288415 | BRISTOL MYERS SQUIBB | Pharmaceutical compositions of 3-(4-amino-1-oxoisoindolin-2yl)-piperidine-2,6-dione |
Jul, 2016
(9 years ago) | |
| US5635517 | BRISTOL MYERS SQUIBB | Method of reducing TNFα levels with amino substituted 2-(2,6-dioxopiperidin-3-yl)-1-oxo-and 1,3-dioxoisoindolines |
Oct, 2019
(6 years ago) | |
| US7855217 | BRISTOL MYERS SQUIBB | Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione |
Nov, 2024
(1 year, 1 month ago) | |
| US7465800 | BRISTOL MYERS SQUIBB | Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione |
Apr, 2027
(1 year, 3 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6561976 | BRISTOL MYERS SQUIBB | Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug |
Aug, 2018
(7 years ago) | |
| US7468363 | BRISTOL MYERS SQUIBB | Methods for treatment of cancers using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione |
Oct, 2023
(2 years ago) | |
| US9155730 | BRISTOL MYERS SQUIBB | Methods for treating non-hodgkin's lymphoma with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione in combination with a second active agent |
May, 2023
(2 years ago) | |
| US8589188 | BRISTOL MYERS SQUIBB | Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug |
Aug, 2018
(7 years ago) | |
| US7119106 | BRISTOL MYERS SQUIBB | Pharmaceutical compositions of 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-aminoisoindoline |
Jul, 2016
(9 years ago) | |
| US8626531 | BRISTOL MYERS SQUIBB | Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated |
Oct, 2020
(5 years ago) | |
| US6755784 | BRISTOL MYERS SQUIBB | Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated |
Oct, 2020
(5 years ago) | |
| US6555554 | BRISTOL MYERS SQUIBB | Isoindolines, method of use, and pharmaceutical compositions |
Jul, 2016
(9 years ago) | |
| US6908432 | BRISTOL MYERS SQUIBB | Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug |
Aug, 2018
(7 years ago) | |
| US8648095 | BRISTOL MYERS SQUIBB | Methods for treating multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione in combination with proteasome inhibitor |
May, 2023
(2 years ago) | |
| US6281230 | BRISTOL MYERS SQUIBB | Isoindolines, method of use, and pharmaceutical compositions |
Jul, 2016
(9 years ago) | |
| US8315886 | BRISTOL MYERS SQUIBB | Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated |
Oct, 2020
(5 years ago) | |
| US8204763 | BRISTOL MYERS SQUIBB | Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug |
Aug, 2018
(7 years ago) | |
| US6045501 | BRISTOL MYERS SQUIBB | Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug |
Aug, 2018
(7 years ago) | |
| US6561977 | BRISTOL MYERS SQUIBB | Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated |
Oct, 2020
(5 years ago) | |
| US6315720 | BRISTOL MYERS SQUIBB | Methods for delivering a drug to a patient while avoiding the occurrence of an adverse side effect known or suspected of being caused by the drug |
Oct, 2020
(5 years ago) | |
| US8288415 | BRISTOL MYERS SQUIBB | Pharmaceutical compositions of 3-(4-amino-1-oxoisoindolin-2yl)-piperidine-2,6-dione |
Jul, 2016
(9 years ago) | |
| US9393238 | BRISTOL MYERS SQUIBB | Methods for treating non-hodgkin's lymphoma with 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione in combination with a second active agent |
May, 2023
(2 years ago) | |
| US7189740 | BRISTOL MYERS SQUIBB | Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes |
Apr, 2023
(2 years ago) | |
| US7968569 | BRISTOL MYERS SQUIBB | Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione |
Oct, 2023
(2 years ago) | |
| US8530498 | BRISTOL MYERS SQUIBB | Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)piperidine-2,6-dione |
May, 2023
(2 years ago) | |
| US8492406 | BRISTOL MYERS SQUIBB | Methods for treatment of follicular lymphoma using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione |
Oct, 2023
(2 years ago) | |
| US9056120 | BRISTOL MYERS SQUIBB | Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine |
Apr, 2023
(2 years ago) | |
| US9101621 | BRISTOL MYERS SQUIBB | Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione after stem cell transplantation |
May, 2023
(2 years ago) | |
| US5635517 | BRISTOL MYERS SQUIBB | Method of reducing TNFα levels with amino substituted 2-(2,6-dioxopiperidin-3-yl)-1-oxo-and 1,3-dioxoisoindolines |
Oct, 2019
(6 years ago) | |
| US8404717 | BRISTOL MYERS SQUIBB | Methods of treating myelodysplastic syndromes using lenalidomide |
Apr, 2023
(2 years ago) | |
| US9101622 | BRISTOL MYERS SQUIBB | Methods for treating newly diagnosed multiple myeloma 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione in combination with dexamethasone |
May, 2023
(2 years ago) | |
| US8741929 | BRISTOL MYERS SQUIBB | Methods using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of mantle cell lymphomas |
Mar, 2028
(2 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE) | Jun 05, 2020 |
| New Indication(I-672) | Jun 05, 2016 |
| New Strength(NS) | Jun 05, 2016 |
| New Indication(I-706) | Feb 17, 2018 |
| Orphan Drug Exclusivity(ODE-49) | Jun 05, 2020 |
| Orphan Drug Exclusivity(ODE-88) | Feb 17, 2022 |
| New Indication(I-796) | May 28, 2022 |
| New Indication(I-797) | May 28, 2022 |
| Orphan Drug Exclusivity(ODE-131) | Feb 22, 2024 |
| Orphan Drug Exclusivity(ODE-241) | May 28, 2026 |
| Orphan Drug Exclusivity(ODE-245) | May 28, 2026 |
Drugs and Companies using LENALIDOMIDE ingredient
Market Authorisation Date: 21 December, 2011
Dosage: CAPSULE
How can I launch a generic of REVLIMID before it's drug patent expiration?
More Information on Dosage
REVLIMID family patents